HomeCompareCMVLF vs GBDC

CMVLF vs GBDC: Dividend Comparison 2026

CMVLF yields 64.94% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.02M in total portfolio value· pulled ahead in Year 7
10 years
CMVLF
CMVLF
● Live price
64.94%
Share price
$3.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$827.5K
Annual income
$205,354.23
Full CMVLF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — CMVLF vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMVLFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMVLF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMVLF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMVLF
Annual income on $10K today (after 15% tax)
$5,519.48/yr
After 10yr DRIP, annual income (after tax)
$174,551.10/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,808,572.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMVLF + GBDC for your $10,000?

CMVLF: 50%GBDC: 50%
100% GBDC50/50100% CMVLF
Portfolio after 10yr
$10.84M
Annual income
$8,328,044.04/yr
Blended yield
76.84%
📊

Analyst Conviction Gap

Where Wall Street is split right now

CMVLF
Analyst Ratings
7
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-0.9
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMVLF buys
0
GBDC buys
0
No recent congressional trades found for CMVLF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMVLFGBDC
Forward yield64.94%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$827.5K$20.85M
Annual income after 10y$205,354.23$16,450,733.83
Total dividends collected$696.1K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: CMVLF vs GBDC ($10,000, DRIP)

YearCMVLF PortfolioCMVLF Income/yrGBDC PortfolioGBDC Income/yrGap
1$17,194$6,493.51$12,492$1,791.70+$4.7KCMVLF
2$28,831$10,434.22$16,527$3,160.58+$12.3KCMVLF
3$47,202$16,352.17$23,588$5,904.90+$23.6KCMVLF
4$75,526$25,019.87$37,141$11,901.65+$38.4KCMVLF
5$118,227$37,414.37$66,205$26,463.38+$52.0KCMVLF
6$181,239$54,736.40$137,452$66,612.65+$43.8KCMVLF
7← crossover$272,346$78,420.28$342,372$195,298.53$70.0KGBDC
8$401,542$110,132.11$1,053,292$686,954.33$651.8KGBDC
9$581,404$151,754.11$4,111,439$2,984,416.95$3.53MGBDC
10$827,457$205,354.23$20,849,974$16,450,733.83$20.02MGBDC

CMVLF vs GBDC: Complete Analysis 2026

CMVLFStock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Full CMVLF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CMVLF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMVLF vs SCHDCMVLF vs JEPICMVLF vs OCMVLF vs KOCMVLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.